Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 8903 results

  1. Transparency of spend

    NICE transparency of spend

  2. Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy (TA1126)

    Evidence-based recommendations on natalizumab originator (Tysabri) and biosimilar (Tyruko) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy in adults.

    Technology appraisal guidance
    Published
    28 January 2026
    View recommendations

    Sections for TA1126

  3. NICE Health Technology Assessment training programme

    We offer a dedicated training opportunity towards achieving competency in either Faculty of Public Health Specialty Training curriculum outcomes.

  4. NICE Health Technology Assessment training programme

    We offer a dedicated training opportunity towards achieving competency in either Faculty of Public Health Specialty Training curriculum outcomes.

  5. NICE training and development opportunities

    Training and development opportunities at NICE

  6. NICE training and development opportunities

    Training and development opportunities at NICE

  7. Concizumab for treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal) (TA1124)

    NICE is unable to make a recommendation on concizumab (Alhemo) for treating haemophilia A or B in people 12 years and over with factor inhibitors. This is because the company did not provide an evidence submission.

    Technology appraisal guidance
    Published
    27 January 2026

    Sections for TA1124

  8. Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma (terminated appraisal) (TA1125)

    NICE is unable to make a recommendation on pembrolizumab (Keytruda) with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma in adults. This is because Merck Sharpe & Dohme will not be proceeding with the evidence submission for the appraisal.

    Technology appraisal guidance
    Published
    27 January 2026

    Sections for TA1125

  9. Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal) (TA972)

    NICE is unable to make a recommendation on sirolimus (Hyftor) for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over. This is because Plusultra pharma did not provide an adequate evidence submission for committee decision-making.

    Technology appraisal guidance
    Last updated
    27 January 2026

    Sections for TA972

  10. Interventional procedures notification

    Home What NICE does Our guidance About interventional procedures guidance {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElem

  11. Website feedback

    Home {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/","name":"Home"}}]}

  12. Subscribe to NICE news international

    Keeping you up-to-date with our worldwide collaborations, opportunities and developments - the NICE International newsletter

  13. Interventional procedures register an interest

    Home What NICE does Our guidance About interventional procedures guidance {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElem

  14. Request for prioritisation clarification

    Home What NICE does Our guidance Prioritising our guidance topics Our prioritisation decisions...

  15. NICE Health Technology Assessment training registration

    Use this form to register your interest for a place on the HTA training programme debrief session.